Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05229900
Other study ID # SGNALPV-001
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date April 21, 2022
Est. completion date December 13, 2023

Study information

Verified date December 2023
Source Seagen Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will test the safety of a drug called SGN-ALPV in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have three parts. Parts A and B of the study will find out how much SGN-ALPV should be given to participants. Part C will use the dose and schedule found in Parts A and B to find out how safe SGN-ALPV is and if it works to treat solid tumor cancers.


Recruitment information / eligibility

Status Terminated
Enrollment 43
Est. completion date December 13, 2023
Est. primary completion date December 13, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants must have one of the following histologically or cytologically confirmed metastatic or unresectable solid tumor types: - Parts A and B - Ovarian cancer - Endometrial cancer - Non-small cell lung cancer (NSCLC) - Gastric cancer, including gastroesophageal junction (GEJ) carcinoma - Cervical cancer - Malignant testicular germ cell tumor (GCT), except for pure teratomas - Malignant ovarian GCT, except for pure teratomas - Malignant extragonadal GCT except for pure teratomas or tumors with primaries arising from CNS - Part C - High-grade serous ovarian cancer (HGSOC): Participants must have HGSOC which has progressed or relapsed within 6 months after previous platinum containing chemotherapy, received 2 to 4 prior anticancer lines of therapy, and at least 1 line of therapy in the platinum-resistant setting. If eligible at least 1 line of therapy must have contained bevacizumab or a biosimilar to bevacizumab. - Endometrial Cancer: Participants must have unresectable locally advance or metastatic endometrial carcinoma and have had at least 1 prior line of therapy. - NSCLC: Participants must have unresectable locally advanced or metastatic NSCLC and have received platinum-based therapy and a PD-(L)1 inhibitor. - Gastric cancer or GEJ carcinoma: Participants must have unresectable locally advanced or metastatic gastric cancer or GEJ carcinoma and have received prior platinum and fluoropyrimidine -based chemotherapy - Participants enrolled in the following study parts should have an appropriate tumor site and agree to a biopsy - Part B dose and schedule optimization cohorts and Part C disease-specific expansion cohorts: pretreatment biopsy, unless clinically infeasible following consultation with the medical monitor. - Part C biology expansion cohort: pretreatment biopsy (required), on-treatment biopsy during Cycle 1 (unless clinically infeasible following consultation with the medical monitor) - Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 - Measurable disease per the RECIST v1.1 at baseline Exclusion Criteria: - History of another malignancy within 3 years of first dose of study treatment or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death. - Known active central nervous system metastases. - Previous receipt of an MMAE-containing agent or an agent targeting ALPP or ALPPL2. - Pre-existing neuropathy = Grade 2 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0

Study Design


Intervention

Drug:
SGN-ALPV
Given into the vein (IV; intravenously)

Locations

Country Name City State
Canada Ottawa Hospital Cancer Centre Ottawa Ontario
Canada University Health Network, Princess Margaret Hospital Toronto Ontario
Spain START Madrid-CIOCC_Hospital HM Sanchinarro Madrid Other
Sweden Karolinska University Hospital Stockholm Other
United Kingdom Sarah Cannon Research Institute UK London Other
United Kingdom The Royal Marsden NHS Foundation Trust (RM) London Other
United States Virginia Cancer Specialists Fairfax Virginia
United States Women's Cancer Care Fresno California
United States START Midwest Grand Rapids Michigan
United States Yale Cancer Center New Haven Connecticut
United States Oklahoma University at Stephenson Cancer Center Oklahoma City Oklahoma
United States Florida Cancer Specialists - Lake Nona Wellington Florida
United States START Mountain Region West Valley City Utah

Sponsors (1)

Lead Sponsor Collaborator
Seagen Inc.

Countries where clinical trial is conducted

United States,  Canada,  Spain,  Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with adverse events (AEs) Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Through 30-37 days after last study treatment, approximately 6 months
Primary Number of participants with laboratory abnormalities Through 30-37 days after last study treatment, approximately 6 months
Primary Number of participants with dose-limiting toxicities (DLTs) Up to 28 days
Primary Number of participants with DLTs by dose level Up to 28 days
Secondary Incidence of antidrug antibodies (ADAs) Through 30-37 days after last study treatment, approximately 6 months
Secondary Area under the concentration-time curve (AUC) PK parameter Through 14 days after last study treatment, approximately 6 months
Secondary Maximum concentration (Cmax) PK parameter Through 14 days after last study treatment, approximately 6 months
Secondary Time to Cmax (Tmax) PK parameter Through 14 days after last study treatment, approximately 6 months
Secondary Apparent terminal half-life (t1/2) PK parameter Through 14 days after last study treatment, approximately 6 months
Secondary Trough concentration (Ctrough) PK parameter Through 14 days after last study treatment, approximately 6 months
Secondary Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) The proportion of participants with an objective response (OR) per investigator. A participant is determined to have an OR if, based on RECIST v1.1, the subject achieves a complete response (CR) or a partial response (PR) after initiation of treatment and at or prior to the end of treatment (EOT) disease assessment. Approximately 2 years
Secondary Duration of objective response (DOR) The time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression (based on radiographic assessments per RECIST v1.1) or death due to any cause. Approximately 2 years
Secondary Progression-free survival (PFS) The time from start of study treatment to first documentation of disease progression or death due to any cause Approximately 2 years
Secondary Overall survival (OS) The time from start of study treatment to death due to any cause Approximately 2 years
Secondary CA-125 response rate according to Gynecological Cancer Intergroup (GCIG) criteria (subjects with ovarian cancer only) The proportion of participants with ovarian cancer who have at least a 50% reduction in CA-125 value from baseline according to GCIG CA-125 criteria Approximately 2 years
Secondary Combined RECIST/CA-125 overall response rate according to GCIG (subjects with ovarian cancer only) The proportion of participants with ovarian cancer whose best response is a CR or PR according to the GCIG combined RECIST and CA-125 criteria Approximately 2 years
See also
  Status Clinical Trial Phase
Completed NCT04879849 - A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers Phase 1
Completed NCT04426825 - A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Phase 2
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT02864394 - Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033) Phase 3
Completed NCT02810457 - Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer Phase 3
Recruiting NCT04592523 - A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
Recruiting NCT04838548 - A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT04077463 - A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer Phase 1
Recruiting NCT05167604 - Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
Recruiting NCT04603807 - A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases Phase 3
Completed NCT04948411 - Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
Active, not recruiting NCT04487080 - A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Phase 3
Not yet recruiting NCT04255836 - Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT01953913 - Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation Phase 3
Recruiting NCT05715229 - Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy Phase 2
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Suspended NCT05421936 - Osimertinib for NSCLC With Uncommon EGFR Mutations
Completed NCT02847377 - A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC N/A
Completed NCT04427072 - Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation Phase 3
Recruiting NCT04823377 - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. N/A